These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2470136)

  • 1. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a.
    Bergh K; Iversen OJ
    Scand J Immunol; 1989 Mar; 29(3):333-41. PubMed ID: 2470136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of monoclonal antibodies against the human anaphylatoxin C5a des Arg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C5a des Arg in plasma.
    Bergh K; Iversen OJ
    J Immunol Methods; 1992 Jul; 152(1):79-87. PubMed ID: 1379278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5 neoepitopes appearing during activation.
    Inoue K
    Complement Inflamm; 1989; 6(3):219-22. PubMed ID: 2472923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies.
    Takeda J; Kinoshita T; Takata Y; Kozono H; Tanaka E; Hong K; Inoue K
    J Immunol Methods; 1987 Aug; 101(2):265-70. PubMed ID: 3611800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
    Perez HD; Hooper C; Volanakis J; Ueda A
    J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies against the major zymosan-induced chemotactic factor in rabbit serum.
    Bergh K; Iversen OJ; Aasbakk K
    J Immunol Methods; 1988 Apr; 108(1-2):179-87. PubMed ID: 3351307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
    Garred P; Mollnes TE; Lea T; Fischer E
    Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.
    Rainard P; Sarradin P; Paape MJ; Poutrel B
    Vet Res; 1998; 29(1):73-88. PubMed ID: 9559522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
    Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
    Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
    Marder SR; Chenoweth DE; Goldstein IM; Perez HD
    J Immunol; 1985 May; 134(5):3325-31. PubMed ID: 3884709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin).
    Perez HD; Kelly E; Chenoweth D; Elfman F
    J Clin Invest; 1988 Jul; 82(1):360-3. PubMed ID: 3392212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts.
    Senior RM; Griffin GL; Perez HD; Webster RO
    J Immunol; 1988 Nov; 141(10):3570-4. PubMed ID: 3183381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg.
    Kew RR; Webster RO
    J Clin Invest; 1988 Jul; 82(1):364-9. PubMed ID: 3392213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive ELISA for the quantitation of human C5a in blood plasma using a monoclonal antibody.
    Schulze M; Götze O
    Complement; 1986; 3(1):25-39. PubMed ID: 3743034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
    Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
    Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.
    Perez HD; Chenoweth DE; Goldstein IM
    J Clin Invest; 1986 Dec; 78(6):1589-95. PubMed ID: 3782473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.